Amgen Inc. (BMV:AMGN)

Mexico flag Mexico · Delayed Price · Currency is MXN
5,667.00
0.00 (0.00%)
At close: Jul 28, 2025
Market Cap2.98T
Revenue (ttm)697.50B
Net Income (ttm)121.26B
Shares Outn/a
EPS (ttm)223.66
PE Ratio24.60
Forward PE14.15
Dividend182.89 (3.23%)
Ex-Dividend DateMay 16, 2025
Volume4,364
Average Volume1,254
Open5,699.64
Previous Closen/a
Day's Range5,667.00 - 5,699.64
52-Week Range5,223.70 - 6,680.00
Beta0.48
RSI54.78
Earnings DateAug 4, 2025

About Smartsheet

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Sector Healthcare
Founded 1980
Employees 28,000
Stock Exchange Mexican Stock Exchange
Ticker Symbol AMGN
Full Company Profile

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial Statements

News

There is no news available yet.